Real KPIs from 20,931 HCPs across 86-week longitudinal panel
Total HCPs
0
86-week longitudinal panel
Labeled Cohort
0
56.9% of total market
Unlabeled Pool
0
633 identified as Business Opportunity Cohort (BoC)
Feature Columns
0
7 feature blocks engineered
Data
Source: All metrics are computed from hcp_analysis_clean.parquet (20,931 HCPs
× 716 columns). KPIs reflect real aggregated prescribing, engagement, and market share data across the
86-week observation window.
Population Distribution
Labeled Target Breakdown
Key Metrics by Segment (Labeled Cohort)
Segment Deep-Dive
Behavioral profiling from actual 716-column feature engineering
Segment A — Traditional
Lowest prescribing volume (0.17 UC TRx/wk). Only 3.8% show Pfizer growth.
Highest rep effort per Rx (0.94 details/TRx). Status-quo prescribers resistant to new therapies.
Population6,406 (53.8%)
UC TRx/week0.171
Pfizer Share of UC0.36%
Active Weeks46.1%
Details per Rx0.94
Low Priority — Baseline
Segment B — Relationship
Highest Pfizer growth signal (9.6% growing). Most efficient rep conversion
(0.44 details/TRx). Broadest promo engagement (2.56 channels). The primary commercial target.
Visualizing the 86-week sequential data fed into the tensors
BC
Dr. Brian Chen
San Francisco, CA — Relationship-Centric
Segment B
Avg Weekly UC TRx
12.2
Brand Preference
Balanced (Low)
Business Value: Steady overall volume with balanced brand adoption. Highly receptive to engagement and an ideal commercial target.
CW
Dr. Catherine Williams
Chicago, IL — Didactic / Cautious
Segment C
Avg Weekly UC TRx
1.7
Brand Preference
Competitor (Brand 2)
Business Value: Strong loyalty to the competitor's brand. A prime target for didactic, evidence-based displacement campaigns.
AL
Dr. Ana Lopez
Houston, TX — Traditional Prescriber
Segment A
Avg Weekly UC TRx
2.5
Brand Preference
Zero Brands
Business Value: High market volume but zero biologic adoption. The ultimate white-space opportunity for market expansion.
Brand1 Adoption & Trajectory
Adoption funnel, growth signals, and recency trends from real data
91.4%
Never Tried Brand1
5.0%
Currently Active
2.6%
Trialed Then Lapsed
Adoption Funnel by Segment (% of each segment)
Adoption Funnel by Segment (Absolute Count)
Growth Signals: Who Is Accelerating?
Pfizer TRx: 86-Week Average vs. Recent 8 Weeks
Commercial Insights
Pfizer vs Brand2 market dynamics across segments
3.90×
Brand2/Pfizer — SEG_A
4.43×
Brand2/Pfizer — SEG_B
4.29×
Brand2/Pfizer — SEG_C
Competitive
Pressure: Brand2 outprescribes Pfizer by 3.9–4.4× across all segments. The gap is widest in
SEG_B (4.43×), the very segment with the highest Pfizer growth trajectory — indicating an active
battleground for share.
Pfizer vs Brand2: Market Share of UC (%) by Segment
Brand2/Pfizer Prescribing Ratio by Segment
UC TRx Volume vs Pfizer Market Share (Labeled HCPs)
Rep Engagement ROI
Measuring commercial efficiency: visits, channels, and prescribing impact
0.94
Details/Rx — SEG_A
0.44
Details/Rx — SEG_B
0.38
Details/Rx — SEG_C
2.1×
SEG_B is 2.1× more efficient than SEG_A
Engagement Metrics by Segment
Rep Visits vs Pfizer Prescribing (Scatter)
Unlabeled HCP Opportunity
Prioritizing 633 unclassified HCPs for commercial outreach
Score < 0.35. Low activity, monitor for emergence.
Coverage Gap:347 of 633 unlabeled HCPs (54.8%) have low/no rep visits (<=5). Click below to view these cohorts.
Live Model Prediction: Segment Classification
Test the live Hugging Face model (SEG_A vs SEG_BC) with sample HCP data.
Opportunity Score Distribution (633 Unlabeled HCPs)
Click a red point to identify the HCP below ↓
HCP Selected
Low/No rep visits (≤5) — high opportunity for outreach
Action Required: This HCP has low or zero recorded representative visits (≤5) yet
shows significant UC prescribing activity. Recommend scheduling an initial detail call.
